Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...

Checkpoint Therapeutics Stock Performance CKPT stock opened at $4.07 on Thursday. The company’s 50 day moving average price is $3.20 and its 200 day moving average price is $3.17. Checkpoint ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...

Hello, everyone, and welcome to MiNK Therapeutics fourth-quarter 2024 financial results call. Please note that this call is being recorded. (Operator Instructions) I'd now like to hand the call over ...

Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

AlphaQuest LLC lowered its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 73.9% during the 4th quarter, ...

Announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the ...

Checkpoint inhibitors such as tislelizumab ... towards realizing the full potential of its Decoy platform. Indaptus Therapeutics has evolved from more than a century of immunotherapy advances.

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq ... in patients with immune checkpoint inhibitor (ICI) -refractory advanced or metastatic solid tumors. Interim results ...

Combining checkpoint inhibitors with immune system activators like Decoy20 could provide a more powerful and sustained anti-tumor response. Indaptus Therapeutics has evolved from more than a century ...